Fig. 5

MALAT1 sponges the tumor-suppressor miR-126-5p in colon cancer cells. a Predicted sequences of miR-126-5p-binding sites within MALAT1, and MALAT1 MT and miR-126-5p MT sequences at the top and bottom, respectively, were used. b, c miR-126-5p was lowly expressed in CRC samples as assessed by the GSE83924 and GSE18392 datasets. d Analysis of miR-126-5p expression levels in colorectal tissues as detected by qRT-PCR. e Analysis of the expression patterns of miR-126-5p in different TNM stages of CRC by qRT-PCR. f Correlation analysis of miR-126-5p and MALAT1 expression levels in CRC tissues by Spearman’s rank correlation coefficient. g Overall survival analysis was carried out to assess the prognostic effect of miR-126-5p in patients with CRC by the Kaplan–Meier method. h HCT116/SW480 cell lysates were incubated with biotin-labeled MALAT1, and miR-126-5p expression levels were determined by qPCR after pull-down. i HCT116/SW480 cell lysates were incubated with biotin-labeled miR-126-5p, and MALAT1 expression was assayed by qPCR after pull-down. j AGO2-RIP was followed by MALAT1 qPCR to assess MALAT1 levels after miR-126-5p overexpression. k Luciferase activity in HCT116 cells co-transfected with miR-126-5p and luciferase reporters containing MALAT1 or mutant transcript. Data were presented as the relative ratio of firefly luciferase activity to Renilla luciferase activity. Three independent experiments were performed. *p < 0.05, **p < 0.01, ***p < 0.001 compared to the control group, by Student’s t-test